Heparin Market, by Product Type (Unfractionated Heparin (UH), Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form (Injection, and Solutions), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
- Report code : CMI62602 |
- Industry :
Pharmaceutical
- Published On : May 2019 |
- Pages : 149 Pages |
- Format :
Heparin Market – Insights
Heparin is used to prevent or treat certain blood vessel, heart, and lung conditions. It is also used in blood transfusion, blood samplings during prophylaxis treatment, and for treatment of blood clotting disorders Heparin may be used to diagnose and treat a serious blood condition called disseminated intravascular coagulation. Heparin is sometimes used alone or in combination with aspirin to prevent pregnancy loss and other problems.
The global heparin market size was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026).
Global Heparin Market Value (US$ Bn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2019)
Increasing incidences of coronary heart disease, pulmonary embolism, and deep vein thrombosis is expected to drive growth of the heparin market
Heparin is widely used clinically for dialysis, deep vein thrombosis (DVT) treatment, and most cardiac surgeries. It is also used to prevent blood clotting during open-heart surgery, kidney dialysis, bypass surgery, and blood transfusions. Kidney dialysis procedure is increasing with rising chronic kidney disease, worldwide. For instance, according to Kidney Care UK 2016 report, about 3 million people in the U.K. are suffering from chronic kidney disease (CKD).
Furthermore, increasing number of surgeries and rising prevalence of diseases such as deep vein thrombosis and coronary heart disease, are fueling demand for heparin, eventually driving growth of the heparin market, during the forecast period. According to the American Heart Association 2018 report, coronary heart disease accounts for 1 in 7 deaths in the U.S., killing over 366,800 people every year. As per the same source, the overall prevalence for myocardial infarction (MI) in the U.S. is about 7.9 million, or 3 percent in U.S. adults.
Heparin Market Restraints
Side effects associated with the use of heparin are the major restraining factors of the market. The main side effect of heparin is bleeding. Heparin can cause spontaneous bleeding from several places in the body including open wounds or surgical sites, intestines and stomach, ovaries and uterus, and mouth and gums. Another serious side effect of heparin is a condition known as heparin-induced thrombocytopenia (HIT) in which heparin induces the body's immune system to develop antibodies against its own platelets, causing risk of bleeding due to reduction in platelets.
Heparin Market - Regional Insights
On the basis of region, the global heparin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe heparin market is expected to generate significant revenue share during the forecast period, owing to growing geriatric population and rising prevalence of long-term survivors of acute myocardial infarction (AMI). Survivors of AMI are at high risk of a recurrent myocardial infarction, as well as other manifestations of cardiovascular disease such as stroke. According to Lancet journal, 2017 report, acute myocardial infarction is the leading cause of hospital admissions and mortality in the UK and across the world.
Asia Pacific heparin market is expected to grow at the highest rate during the forecast period, owing to increasing incidence of myocardial infarction among regional population. According to a study published by National Center for Biotechnology Information (NCBI) in 2015, Asian population is more susceptible to MI than white people. There are 50% higher cases of MI in South Asians than in white people in the UK.
Global Heparin Market Share (%), By Region 2017
Source: Coherent Market Insights Analysis (2019)
Heparin Market - Competitive Landscape
Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
Heparin is an anticoagulant used to decrease the clotting ability of blood and help to prevent harmful clots from forming in blood vessels. It is sometimes referred as a blood thinner, although it does not actually thin the blood. Heparin does not dissolve already formed blood clots, but it can prevent the clots from becoming larger and causing more serious problems. Pharmaceutical-grade heparin is derived from animal tissue. Heparin is commonly used in the treatment of coronary heart disease, pulmonary embolism, deep vein thrombosis, and atrial fibrillation, and in the prevention of thrombosis during extracorporeal membrane oxygenation and cardiopulmonary bypass.
Market Dynamics
Rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis is one of the major factors for increased demand of heparin drugs in the market. Myocardial infarction (MI) is one of the major complications of coronary heart disease. According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centres for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affects nearly 900,000 individuals in the U.S. each year.
Despite major applications in chronic conditions, heparin is poorly absorbed by the intestine, therefore it must be given intravenously or subcutaneously. Moreover, the drug creates a significant risk of excessive bleeding due to anticlotting effect. Heparin also induce conditions such as thrombocytopenia (reduced number of circulating platelets) and hypersensitivity reactions. These factors can hamper the heparin market, during the forecast period.
Key features of the study:
- This report provides in-depth analysis of the heparin market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global heparin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global heparin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for heparin market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Heparin Market, By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- Global Heparin Market, By Dosage Form:
- Injection
- Solutions
- Global Heparin Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Product Type:
- Unfractionated Heparin (UH)
- Low Molecular Weight Heparin (LMWH)
- Ultra-low Molecular Weight Heparin (ULMW)
- By Dosage Form:
- Injection
- Solutions
- By Country:
- North America
- Company Profiles
- Anselm Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Baxter International Inc.
- Braun Melsungen AG
- Bristol-Myers Squibb Co.
- Reddy’s Laboratories Ltd.
- Fresenius SE & Co. KGaA
- Leap Labchem Co.
- LEO Pharma A/S
- Pfizer, Inc.
- Sanofi S.A.
- Syntex S.A.
- Teva Pharmaceutical Industries Ltd.
- United Biotech (P) Ltd.
- Anselm Pharmaceuticals*
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Dosage Form
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Overview
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Supply Chain Analysis
- Regulatory Landscape
- Epidemiology Analysis
- Global Heparin Market, By Product Type, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Unfractionated Heparin (UH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Low Molecular Weight Heparin (LMWH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Ultra-low Molecular Weight Heparin (ULMW)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Global Heparin Market, By Dosage Form, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Global Heparin Market, By Region, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2016 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Dosage Form, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Anselm Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Baxter International Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- B. Braun Melsungen AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Co.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Dr. Reddy’s Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Fresenius SE & Co. KGaA
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Leap Labchem Co.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LEO Pharma A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Syntex S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- United Biotech (P) Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
*Browse 33 market data tables and 21 figures on "Heparin Market” - Global forecast to 2026”.
Related Insights :
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.